Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Summary
Parabilis Medicines closed an upsized IPO and sold additional shares through the underwriters’ full overallotment exercise. The company also completed a concurrent private placement to Regeneron Pharmaceuticals. Total 2026 funding surpassed $1.2 billion before fees and expenses, according to the release. Parabilis says the capital will support development of its Helicons platform and transformative medicines for hard-to-target proteins.
Funding
Amount
$770.5M
Total raised
Date
June 11, 2026
Announcement date
Investors
Leerink Swann & Company, Evercore Partners, Regeneron Pharmaceuticals, Guggenheim Partners
Lead investors
Company
parabilismed.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected